We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Renal Cell Carcinoma

Journal Scan / Review · August 06, 2020

Exposure-Response Modeling of Cabozantinib in RCC

Cancer Treatment Reviews


Additional Info

Cancer Treatment Reviews
Exposure-Response Modeling of Cabozantinib in Patients With Renal Cell Carcinoma: Implications for Patient Care
Cancer Treat. Rev 2020 Jun 24;[EPub Ahead of Print], D Castellano, J Pablo Maroto, F Benzaghou, N Taguieva, L Nguyen, DO Clary, E Jonasch

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading